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Examining the clinical use of hemochromatosis
genetic testing
Matthew B Lanktree MD PhD1, Bruce B Lanktree MD, Guillaume Paré MD MSc2, John S Waye PhD2,
Bekim Sadikovic PhD2, Mark A Crowther MD1
MB Lanktree, BB Lanktree, G Paré, JS Waye, B Sadikovic,
MA Crowther. Examining the clinical use of hemochromatosis
genetic testing. Can J Gastroenterol Hepatol 2015;29(1):41-45.
Background: Hereditary hemochromatosis leads to an increased

lifetime risk for end-organ damage due to excess iron deposition.
Guidelines recommend that genetic testing be performed in patients
with clinical suspicion of iron overload accompanied by elevated
serum ferritin and transferrin saturation levels.
Objective: To evaluate guideline adherence and the clinical and
economic impact of HFE genetic testing.
Methods: The electronic charts of patients submitted for HFE testing in 2012 were reviewed for genetic testing results, biochemical
markers of iron overload and clinical history of phlebotomy.
Results: A total of 664 samples were sent for testing, with clinical,
biochemical and phlebotomy data available for 160 patients. A positive
C282Y homozygote or C282Y/H63D compound heterozygote test
result was observed in 18% of patients. Patients with an at-risk HFE
genotype had significantly higher iron saturation, serum iron and
hemoglobin (P<0.001), without higher ferritin or liver enzyme levels.
Fifty percent of patients referred for testing did not have biochemical
evidence of iron overload (transferrin saturation >45% and ferritin
level >300 μg/L). Patients were four times more likely to undergo phlebotomy if they were gene test positive (RR 4.29 [95% CI 2.35 to 7.83];
P<0.00001).
Discussion: One-half of patients referred for testing did not
exhibit biochemical evidence of iron overload. Many patients with
biochemical evidence of iron overload, but with negative genetic test
results, did not undergo phlebotomy. A requisition to determine clinical indication for testing may reduce the use of the HFE genetic test.
Finally, improvement of current genetic test characteristics would
improve rationale for the test.
Conclusion: A significant proportion of hemochromatosis genetic
testing does not adhere to current guidelines and would not alter
patient management.
Key Words: Genetic testing; Hemochromatosis; Iron; Phlebotomy

H

ereditary hemochromatosis is a common genetic condition in
which elevated total body iron stores leads to iron deposition in
the liver, heart, pancreas, skin, joints, pituitary gland and testes,
resulting in liver cirrhosis, heart failure, arthritis, diabetes, skin bronzing, endocrine abnormalities and cancer (1). In 1996, two missense
mutations in the hemochromatosis gene (HFE) were identified to be a
cause of hereditary hemochromatosis, leading to an increase in our
understanding of iron metabolism, the pathophysiology of hemochromatosis and the genetic test that is still performed today (2).
The genetic test for hemochromatosis most commonly involves
genotyping of a cysteine-to-tyrosine substitution at amino acid position
282 (C282Y) and a histidine-to-aspartic acid substitution at amino acid
position 63 (H63D) in the HFE gene. A positive genetic test is defined
as two copies (homozygosity) of the C282Y allele, or one C282Y allele

Examen de l’utilisation clinique du test de dépistage
génétique de l’hématochromatose
HISTORIQUE : L’hématochromatose héréditaire s’associe à un plus
grand risque à vie de dommage aux organes cibles causé par un dépôt
excessif de fer. Les lignes directrices recommandent d’effectuer un test de
dépistage génétique en cas de suspicion clinique de surcharge en fer
accompagnée d’un taux élevé de ferritine sérique et d’une saturation de la
transferrine.
OBJECTIF : Évaluer le respect des lignes directrices et les répercussions
cliniques et économiques du test HFE.
MÉTHODOLOGIE : Les chercheurs ont examiné le dossier électronique
des patients qui devaient subir un test HFE en 2012 afin de connaître
leurs résultats génétiques, leurs marqueurs biochimiques de surcharge en
fer et leurs antécédents cliniques de phlébotomie.
RÉSULTATS : Au total, 664 échantillons ont été envoyés au dépistage,
et les chercheurs ont obtenu les données cliniques, les données biochimiques et la phlébotomie de 160 patients. Chez 18 % d’entre eux, le test
a décelé une homozygotie C282Y ou une hétérozygotie composite C282Y
et H63D. Les patients présentant un génotype HFE à risque avaient une
saturation en fer, en fer sérique et en hémoglobine considérablement plus
élevée (P<0,001), sans augmentation de leur taux de ferritine ou
d’enzymes hépatiques. Cinquante pour cent des patients aiguillés pour le
test ne présentaient pas de manifestations biochimiques de surcharge en
fer (saturation en transferrine >45 % et taux de ferritine >300 μg/L). Les
patients étaient quatre fois plus susceptibles de subir une phlébotomie si le
test génétique était positif (RR 4,29 [95 % IC 2,35 à 7,83]; P<0,00001).
EXPOSÉ : La moitié des patients aiguillés pour subir le test ne présentaient pas de manifestations biochimiques de surcharge en fer. De nombreux patients qui présentaient des manifestations biochimiques de
surcharge en fer, mais dont les résultats du test génétique étaient négatifs,
n’ont pas subi de phlébotomie. Une réquisition pour établir l’indication
clinique d’effectuer le test HFE peut en réduire l’utilisation. Enfin, en
améliorant les caractéristiques du test génétique actuel, on en justifierait
mieux l’utilisation.
CONCLUSION : Une proportion marquée de tests génétiques de
l’hémochromatose ne respecte pas les lignes directrices et ne changerait
pas la prise en charge des patients.

with an H63D allele on the other chromosome, termed ‘compound
heterozygosity’. Fewer than 0.5% of individuals of European ancestry are
homozygous for C282Y, with lower prevalence in other ethnicities (3).
The penetrance of the C282Y variant for iron accumulation leading to end-organ disease in one’s lifetime, which also represents the
positive predictive value of the genetic test, has been evaluated in
prospective, retrospective and cross-sectional studies (4). Differences
in study populations and disease definitions have yielded a wide range
of estimates from 0% to 75% (4). Cross-sectional studies including
large numbers of patients may underestimate lifetime risk because they
may evaluate patients before they have developed the outcome and
may rely on imperfect measures of disease diagnosis (5). Alternatively,
prospective studies that follow small numbers of patients may identify
disease that may not be clinically relevant (6). Moreover, penetrance
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is significantly different between men and premenopausal women,
given the protection yielded by menses. Nevertheless, overall estimates from a meta-analysis of current clinical guidelines suggests a
lifetime penetrance and, hence, positive predictive value of 13% (4).
The sensitivity of the current hemochromatosis genetic test is
represented by the prevalence of individuals who test positive if they
have developed end-organ iron overload damage. Estimates are again
affected by the population observed and the gold standard used for
diagnosis, but have ranged from 75% to 90% (4,7-9). Given that
hemochromatosis exists in nonwhite populations, and the low prevalence of C282Y in nonwhite ethnicities, the sensitivity of the test is
reduced in these populations (10). Non-C282Y HFE polymorphisms
(such as H63D) have smaller effects on iron accumulation risk and
may improve the sensitivity of a genetic test, but consequently negatively affect specificity because the penetrance of H63D is quite low
(11). In general, patients with a negative genetic test may still develop
iron overload, while 80% to 90% of individuals with a positive genetic
test may never develop iron overload (4).
Over the past decade, considerable debate has occurred with regard
to the appropriate clinical context in which to order genetic testing for
hemochromatosis (11-13). Current guidelines published by the
European Association for the Study of the Liver (4) and American
Association for the Study of Liver Diseases (7) recommend against
genetic testing for hemochromatosis in the absence of clinical suspicion for hemochromatosis, with the exception of siblings of confirmed
HFE C282Y homozygotes with clinical hemochromatosis (ie, genetic
screening of unaffected individuals is inappropriate). Hence, genetic
testing of patients should be limited to individuals with elevated transferrin saturation (>45% in women and >50% in men) and serum ferritin level (>300 μg/L). Strategies investigating alternative causes of
elevated ferritin levels and transferrin saturation followed by serial
genetic investigations has also been proposed (13,14).
Phlebotomy can be both diagnostic and therapeutic because it
removes excess iron, and the response to phlebotomy is an indicator of
the quantity of iron present (4). Individuals with pathological iron overload will require removal of many grams of iron while those with other
causes of elevated ferritin levels and transferrin saturation will generally
experience a rapid fall in iron levels (4). Phlebotomy should be initiated
in patients with suspected iron excess and continued until ferritin level
has dropped to <50 μg/L, although no randomized control trials have
been performed to support its use (4). Phlebotomy is safe in patients
with advanced liver fibrosis or cirrhosis, and may improve arthropathies,
diabetes, hypogonadism and hypothyroidism (4).
The cost of genetic testing for hemochromatosis has not changed
substantially in the past decade despite immense improvements in
genotyping technology. The cost of DNA extraction and singlenucleotide genotyping in a high-throughput research environment has
plummeted, but because overhead costs, data storage and data integrity
issues have remained constant, cost estimates from $150 to $500 per
test have persisted (15).
To better understand the use of hemochromatosis genetic testing in
current practice, we sought to identify the clinical and biochemical
characteristics of patients submitted to a tertiary care laboratory in
Hamilton, Ontario. Finally, we examined factors that may have
impacted the clinician’s decision to provide phlebotomy.

Methods

Ethics approval to retrospectively review patient records was granted
by the Hamilton Integrated Research Ethics Board (approval number
13-323-C). Data were collected from the electronic patient record
(EPR) of Hamilton Health Sciences and included all patients referred
for genetic testing for hemochromatosis in the 2012 calendar year.
Hamilton Health Sciences is an academic tertiary care medical facility serving a catchment of 2.3 million Canadians. In total, the EPR
of 620 patients were manually accessed to obtain genetic test results,
biochemical markers of iron overload, biochemical markers of endorgan damage resulting from iron accumulation and clinical history of
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phlebotomy. Specifically, data included genotype at HFE C282Y and
H63D, maximum ferritin, transferrin saturation, aspartate transaminase, alanine transaminase, gamma-glutamyl transpeptidase, alkaline
phosphatase, glycated hemoglobin, fasting glucose, hemoglobin concentration and minimum mean corpuscular volume. Phlebotomy
status was primarily ascertained by examining the ‘reason for visit’ field
within the appointment scheduling system of the EPR, as well as
manual review of the free-text consultation and progress notes. The
type of physician who had made the referral was also available.
Unfortunately, patients who had not required hospitalization for any
reason, nor received evaluation by a hematologist or gastroenterologist, but were referred for genetic testing by a community primary care
physician would not have clinical data available in the Hamilton
Health Sciences EPR.
Data are expressed as counts and percentages for categorical variables, and mean ± SD or median (interquartile range) for continuous
data depending on their distribution. Comparisons between groups
were performed using χ2 and ANOVA tests.

Results

In total, 664 patients were submitted for hemochromatosis genetic testing, including nine repeated tests; 177 (26%) of patients were female.
The observed minor allele frequency was 18% for C282Y and 20% for
H63D, yielding 49 (8.1%) C282Y homozygotes and 49 (8.1%) C282Y/
H63D compound heterozygotes, corresponding to an overall positive
test rate of 16.2% (Table 1). Of 655 patients, 449 (68.5%) did not carry
a C282Y allele. There was no significant difference in the rate of positive
tests ordered by family physicians verses those ordered by specialists.
Of those referred for testing, clinical and biochemical data were
available for 160 patients. Transferrin saturation and ferritin level data
were available for 96 patients, and evidence of iron overload (measured transferrin saturation >45% and ferritin >300 μg/L) was present
in 48 (50%). Comparing biochemical characteristics between those
with positive hemochromatosis genetic testing results (either C282Y/
C282Y or C282Y/H63D) had significantly higher transferrin saturation, hemoglobin and serum iron concentrations (P<0.001) (Table 2).
There was no increase in either ferritin or liver enzyme levels in the
group with a positive genetic test.
Phlebotomy was performed in 33 patients, 20 of whom were hemochromatosis gene test positive and 13 who were not. For a given ferritin level or transferrin saturation, patients were significantly more
likely to undergo phlebotomy if they were gene test positive (P<0.01).
The likelihood of undergoing phlebotomy for a given ferritin level and
transferrin saturation is presented in decision-tree format in Figure 1.
Examining the test characteristics of the hemochromatosis genetic test
for subsequent need for phlebotomy in this clinically ascertained
sample, in which genotype likely affected the decision to provide
phlebotomy, the sensitivity for subsequent need for phlebotomy was
60% (95% CI 43% to 75%), with a specificity of 82% (95% CI 75% to
88%) and an RR of 4.29 (95% CI 2.35 to 7.83 [Fisher’s exact
P<0.00001]). The positive predictive value was 47% (95% CI 35% to
59%) and the positive likelihood ratio was 3.47 (95% CI 2.06 to 5.41).

Discussion

The results of a retrospective analysis of 664 hemochromatosis genetic tests performed at a tertiary care academic medical centre in the
2012 calendar year indicates that a substantial proportion of hemochromatosis genetic testing was performed out of accordance with
currently published guidelines. Additionally, hemochromatosis genetic testing appears to be affecting the decision to provide phlebotomy without solid evidence to support the practice. We believe that
more stringent access to genetic testing for hemochromatosis may
reduce the amount of unnecessary testing without adversely affecting
patient care. Finally, improvements in the test characteristics of the
hemochromatosis genetic test, and prospective randomized studies
designed to appropriately direct its use, would lead to both cost savings
and improvement in patient care.
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Table 1
Genetic testing results
HFE genotype

Table 2
Clinical characteristics according to HFE test result
Specialists*

Total

282Y/282Y

Family physicians
20 (7.1)

29 (9.0)

49 (8.1)

Characteristic

282Y/63D

22 (7.8)

27 (8.4)

49 (8.1)

n

Negative

241 (85.2)

265 (82.6)

506 (83.8)

HFE test result
Positive

Age, years

Data presented n (%). *Specialists include (in order of prevalence): gastroenterologists, hematologists and cardiologists. HFE Hemochromatosis gene

117

54.3±13.6

56.3±13.7

Female sex, n (%)

13 (28)

35 (30)

Maximum ferritin, μg/L

864±607

901±862

Maximum transferrin saturation, %

62±23*

46±20*

121±6.5*

21.5±7.7*

Maximum hemoglobin, g/L

155±9.4*

144±20*

Minimum mean corpuscular volume, fL

93.8±5.8

91±11

68±20

1001±36

Maximum serum iron, umol/L

Who should undergo genetic testing for hemochromatosis?
Current guidelines suggest confirmatory genetic testing in patients
with clinical suspicion and biochemical evidence of iron accumulation
(4,7). A diagnostic and therapeutic trial of phlebotomy may be indicated in these patients regardless of genetic testing results.
Nevertheless, ferritin levels and transferrin saturations were available for only 96 patients sent for genetic testing and only one-half of
these fulfilled biochemical criteria for possible iron overload. It is possible that more of the patients had ferritin and transferrin testing performed, which was unavailable for the present retrospective analysis;
however, a large proportion of patients who are undergoing the genetic
test do not have biochemical evidence of iron overload.
It is possible that a proportion of patients that received genetic
testing without iron accumulation were first-degree relatives of
homozygous C282Y hemochromatosis patients, and negative genetic
testing results may reduce the need for serial transferrin and ferritin
measurements in the future. This remains a poor explanation because
68.5% of those tested did not carry a C282Y allele, which is unlikely
if they are a first-degree relative of homozygous C282Y hemochromatosis patients. The cost for ferritin and transferrin measurements is
approximately $25 each (16). Additionally, first-degree relatives may
still be at elevated risk if a non-HFE C282Y mechanism is the reason
for iron accumulation.
So-called ‘shotgun’ investigations, in which multiple investigations are simultaneously ordered to cover a range of potential pathogenic mechanisms in patients with elevated liver enzyme levels,
porphyria cutanea tarda, hepatocellular carcinoma, type 1 diabetes or
well-defined chondrocalcinosis, may represent a portion of the hemochromatosis genetic testing. However, given the slow rate of disease
progression of hemochromatosis, a staggered approach in which genetic testing follows measurement of ferritin levels and transferrin saturation appears to be more appropriate.
In general, our results suggest that a large proportion of current
hemochromatosis genetic testing is unlikely to provide diagnostic certainty, change patient management or comply with current guidelines.

Negative
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Maximum aspartate aminotransferase, U/L
Maximum alanine aminotransferase, U/L

110±30

156±42

Maximum gamma-glutamyl transpeptidase, U/L

55±17

208±75

Maximum alkaline phosphatase, U/L

66±12

151±41

Viral hepatitis, n (%)

2 (4.7)

11 (9.4)

27 (64)*

12 (10)*

Received phlebotomy, n (%)

Data presented as mean ± SD unless otherwise indicated. *P<0.001. HFE
Hemochromatosis gene

Efforts to improve education regarding the indications for hemochromatosis genetic testing may reduce the quantity of unnecessary testing.
Finally, a laboratory requisition form for hemochromatosis genetic
testing, including the indication for the test and measured ferritin levels and transferrin saturation, would enable more accurate evaluation
of hemochromatosis genetic testing in the future and would prevent
unnecessary testing.
Should the current HFE genetic test affect the decision to
phlebotomize?
Clinicians need to incorporate information from history, physical
investigations and patient preferences to evaluate the pros and cons of
phlebotomy in a particular patient. Factors to be considered before offering phlebotomy are included in Box 1. The decision-tree in Figure 1
attests that the decision is not simply based on ferritin level, transferrin saturation and genotype. However, genotype does appear to affect
the decision to provide phlebotomy in these data. To date, there exists
a dearth of evidence that individuals with HFE C282Y-associated
hemochromatosis respond differently to phlebotomy than those with
non-HFE C282Y iron accumulation. Thus, while a positive test may
increase the likelihood of pathogenic iron accumulation, a trial of
phlebotomy is the gold standard for diagnosis.

Ferritin

<300 μg/L

300 –1000 μg/L

>1000 μg/L

Transferrin

HFE

Transferrin

≥0.45

<0.45

HFE

HFE

≥0.45

<0.45

HFE

HFE

−

+

−

+

−

+

−

+

−

+

Phlebotomy
0/14

Phlebotomy
3/6

Phlebotomy
3/23

Phlebotomy
1/1

Phlebotomy
2/13

Phlebotomy
7/14

Phlebotomy
2/8

Phlebotomy
2/2

Phlebotomy
4/15

Phlebotomy
5/5

Figure 1) Decision-tree analysis. HFE Hemochromatosis gene
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Box 1
Factors affecting to the decision to phlebotomize
• Serum iron parameters (transferrin saturation, ferritin)
• Hemoglobin
• Presence of alternative explanation
○ Alcohol use/abuse
○ Metabolic syndrome
○ Nonalcoholic steatohepatitis
○ Viral hepatitis

• Inflammatory states (infectious, autoimmune)
• Noninvasive liver imaging (ultrasound, Fibroscan [Ecosens, France],
computed tomography)

• Evidence of iron overload on liver biopsy
• Hemochromatosis gene (HFE) genotype
• Comorbidities
• Patient’s goals of care
• Ease of access to facilities
• Tolerability of procedure (orthostasis)

Can hemochromatosis genetic test performance be improved?
Hemochromatosis is a complex disease with substantial genetic heterogeneity. While HFE C282Y is found in 80% of patients with clinical
hemochromatosis (4), other genetic causes of hemochromatosis have
been described. These include rare mutations and deletions in HFE
undetected by standard clinical tests, and mutations in four other genes
(hepcidin [HAMP], hemojuvelin [HFE2, previously HJV], transferrin
receptor 2 [TFR2] and ferroportin [SLC40A1]) (17,18). Mutations that
affect ferritin concentration (a common marker used to identify iron
overload) but do not lead to iron accumulation, have been observed in
the ferritin light chain (FTL) gene (19). Adding to the complexity,
common polymorphisms in 14 additional genes have been associated
with variation in iron metabolism in the general population and in
hemochromatosis patients (10,20-22). Environmental exposures,
including diet, alcohol and medication use, can also significantly alter
the risk of pathological iron accumulation. Given the complexity, it is
not surprising that the genotyping of only the two single-nucleotide
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polymorphisms in HFE yields a test that is not particularly sensitive nor
specific for iron accumulation leading to end-organ damage. Test performance in non-European ethnicities is even worse given the low
background frequency of the C282Y allele (10).
Schranz et al (13), suggested a staggered approach to testing with
targeted sequencing of HFE, TFR2, HFE2, (HJV), HAMP and
SLC40A1 (13). Given the drastically declining cost of DNA sequencing via sequence capture and next-generation sequencing technologies, the production of a test that obtains all DNA variations in iron
metabolism genes at a low cost is needed. A similar strategy has already
been used for conditions such as hypertrophic cardiomyopathy and dyslipidemia (23,24). Barriers to the interpretation of next-generation
sequencing data exist as many variants of unknown significance.
Nevertheless, commercial testing using this strategy is already available <www.invitae.com/en/physician/condition-detail/CND0033/>.
Limitations of the current study
The most significant limitation of the current study was its retrospective chart review design. Data were extracted from the records of a
selected hospital-based population, biasing the study toward the presence of more severely affected patients. Patients may have been
instructed to attend blood donation clinics, which would not have
entered our records as having undergone a phlebotomy. While a clinical trial randomly assigning patients to phlebotomy may not be ethically feasible, a prospectively collected cohort with stringent data
collection protocols may mitigate bias in the evaluation of nextgeneration genetic tests for hemochromatosis.

Conclusions

The present retrospective chart review suggests that a large percentage of hemochromatosis genetic testing was performed on
patients without iron accumulation and would not alter their diagnosis, prognosis or management. Patients with evidence of iron
overload were more likely to receive phlebotomy in the presence
of a positive test when those with negative tests, especially nonEuropeans, may still benefit.
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